PathAI on Thursday announced the launch of its digital pathology platform and AIM-PDL1 algorithm for non-small cell lung cancer (NSCLC) in partnership with 13 leading academic medical centers, health systems, reference laboratories and independent pathology institutions across the U.S.
AISight, PathAI's digital pathology platform, and AIM-PD-L1 NSCLC RUO, which quantitates the percentage of PD-L1 positive tumor and immune cells in NSCLC samples, are available to the 13 institutions as part of an early access program to gather real-world evidence about the use of digital pathology tools.
The network of laboratories will be the first to access PathAI's growing menu of algorithm products across oncology and non-oncology indications.
The following organizations are participants in the early access program:
- Reference Laboratories
- Caris Life Sciences
- NeoGenomics Laboratories
- Independent Pathology Laboratories
- Celligent Diagnostics
- PathAI Diagnostics
- Academic Medical Centers & Health Systems
- Baylor Scott & White Healh
- Cleveland Clinic
- Inova Health
- Medstar Health
- Penn State Health
- SUNY Upstate Medical University
- University of Pittsburgh Medical Center